Genomic Profiling Reveals Multiple Resistance Mechanisms of Cancers Against KRAS Inhibitors
KRAS is a major cancer driver mutated in around 30%-40% of colon cancers and 15%-20% of lung cancers. Developing inhibitors for KRAS is a challenge, and until very recently, KRAS …
Read More